Day One Biopharmaceuticals, Inc. Files Amended 2025 Annual Report: Key Details for Investors

Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) has filed its Amendment No. 1 to the Annual Report on Form 10-K/A for the fiscal year ended December 31, 2025. This amendment provides comprehensive updates, including executive compensation details, governance changes, and compliance information, which are critical for shareholders and may influence the company’s share value.

Key Highlights from the Report

• Filing Purpose and Scope:
  • The amendment includes information required by Parts II and III of Form 10-K, not included in the original filing. New certifications by the principal executive and financial officers have been added in compliance with Section 302 of the Sarbanes-Oxley Act.
  • The amendment does not update disclosures for subsequent events after the original filing date (February 24, 2026).
• Corporate Details:
  • Headquarters: 1800 Sierra Point Parkway, Suite 200, Brisbane, CA 94005
  • Common Stock Outstanding as of April 15, 2026: 103,334,169 shares
  • Exchange: Nasdaq Global Select Market under the symbol “DAWN”
• Shareholder Value Metrics:
  • Market Capitalization: The aggregate market value of common equity held by non-affiliates as of June 30, 2025, is disclosed (exact value not specified in extracted pages, but typically found in complete filing).
• Regulatory and Compliance Status:
  • Day One is not a shell company.
  • The company is a “Smaller Reporting Company” but not an “Emerging Growth Company.”
  • There were no material weaknesses or reportable errors in its internal controls; the financial statements do not reflect a correction of errors.
  • The company has adopted an Insider Trading Policy covering directors, officers, employees, consultants, and contractors, prohibiting hedging, pledging, and trading derivative securities tied to company stock.
  • No directors, officers, or major shareholders failed to file Section 16(a) reports on time in 2025, except for two late filings each by Jeremy Bender, Adam Dubow, and Charles York, regarding equity awards and sales to cover taxes.
• Executive Compensation and Governance
  • Compensation Philosophy: The executive compensation program is designed to closely align management incentives with company performance and shareholder interests. Key features include:
    • Competitive total compensation packages
    • Performance-based annual incentives tied to company goals in finance, R&D (notably the DAY301 program), and corporate development
    • Equity compensation through stock options and RSUs to encourage long-term value creation
  • 2025 Executive Compensation Elements:
    • Base salary, annual incentive (cash bonus), and long-term equity incentives (stock options and RSUs)
    • For example, a listed executive received a base salary of \$325,000 (specific executives and broader details are tabulated in the report)
    • Target bonus opportunities and total equity award values are disclosed for named executive officers (NEOs)
  • Compensation Committee and Governance:
    • The Compensation Committee oversees executive pay, sets performance metrics, and administers incentive plans.
    • Alpine, an external consultant, advises the Committee on market practices and public disclosures.
  • Board Practices:
    • Day One maintains a comprehensive Code of Business Conduct and Ethics, available on their investor relations website.
    • The board has implemented robust compliance, audit, and compensation oversight, including cybersecurity and sustainability matters.
• Equity Compensation Plans:
  • Day One discloses all securities authorized for issuance under equity compensation plans, with further details in Item 12 of the filing.

Shareholder-Relevant and Potentially Price-Sensitive Information

• Executive Compensation Structure: The detailed disclosure of executive compensation, including target bonuses and equity awards, demonstrates a strong alignment with performance and shareholder value. This may bolster investor confidence in the company’s governance and compensation practices.
• Governance and Compliance: The company’s clear focus on compliance (no significant restatements or control weaknesses), adoption of a restrictive insider trading policy, and robust board oversight may be viewed positively by institutional investors and could support share price stability.
• Organizational Stability: The absence of material errors, restatements, or unreported insider transactions during 2025 (aside from minor filing delays) suggests strong internal controls and management integrity, which are favorable for long-term investors.
• Business and R&D Focus: The emphasis on performance metrics tied to pivotal programs (e.g., DAY301) and corporate development highlights continued investment in pipeline advancement, potentially impacting future valuation.

Conclusion

The amended 10-K/A solidifies Day One Biopharmaceuticals’ commitment to transparency, performance-based compensation, and governance best practices. While no single item in the amendment is likely to cause immediate, significant share price volatility, the aggregate of robust compliance, competitive executive pay, and a clear focus on long-term value creation should be viewed as supportive of investor confidence. Any future developments in key programs, financial performance, or governance changes will remain critical to watch.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors are encouraged to review the full filing and consult with their financial advisors before making investment decisions. The article is based on publicly available information as of the date of the amended 10-K/A filing and may not reflect subsequent events or disclosures.

View Day One Biopharmaceuticals, Inc. Historical chart here